Resveratrol modulates cytokine-induced JAK/STAT activation more efficiently than 5-aminosalicylic acid: An in vitro approach

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Serra, Diana ^a,b   Rufino, Ana T ^a,b   Mendes, Alexandrina F ^a,b   Almeida, Leonor M ^a,b   Dinis, Teresa C P ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; GAMMA INTERFERON; I KAPPA B ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1ALPHA; JANUS KINASE; MESALAZINE; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; RESVERATROL; STAT PROTEIN; STAT1 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; STILBENE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL NUCLEUS; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; INTESTINE EPITHELIUM CELL; NEGATIVE FEEDBACK; PROSTAGLANDIN SYNTHESIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; HT 29 CELL LINE; METABOLISM; PHYSIOLOGY;

CYTOKINES; HT29 CELLS; HUMANS; IN VITRO TECHNIQUES; JANUS KINASES; MESALAMINE; STAT TRANSCRIPTION FACTORS; STILBENES;

EID: 84907495359     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109048     Document Type: Article

References (54)

1. Bahadoran Z, Mirmiran P, Azizi F. (2013) Dietary polyphenols as potential nutraceuticals in management of diabetes: a review. J Diabetes Metab Disord 12: 43-51.
2. Vauzour D, Rodriguez-Mateos A, Corona G., Oruna-Concha MJ, Spencer J.P. (2010) Polyphenols and human health: prevention of disease and mechanisms of action. Nutrients 2: 1106-1131.
3. Scalbert A, Manach C, Morand C., Remesy C, Jimenez L. (2005) Dietary polyphenols and the prevention of diseases. Crit Rev Food Sci Nutr 45: 287-306.
4. Manach C, Scalbert A, Morand C., Remesy C, Jimenez L. (2004) Polyphenols: food sources and bioavailability. Am J Clin Nutr 79: 727-747.
5. Romier B, Schneider YJ, Larondelle Y, During A. (2009) Dietary polyphenols can modulate the intestinal inflammatory response. Nutr Rev 67: 363-378.
6. Martin AR, Villegas I, Sanchez-Hidalgo M, de la Lastra CA (2006) The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br J Pharmacol 147: 873-885.
7. Paixao J, Dinis TC, Almeida L.M. (2012) Malvidin-3-glucoside protects endothelial cells up-regulating endothelial NO synthase and inhibiting peroxynitrite-induced NF-kB activation. Chem Biol Interact 199: 192-200.
8. Serra D, Paixao J, Nunes C., Dinis TC, Almeida L.M. (2013) Cyanidin-3-glucoside suppresses cytokine-induced inflammatory response in human intestinal cells: comparison with 5-aminosalicylic acid. PloS one 8: e73001.
9. Paixao J, Dinis TC, Almeida L.M. (2011) Dietary anthocyanins protect endothelial cells against peroxynitrite-induced mitochondrial apoptosis pathway and Bax nuclear translocation: an in vitro approach. Apoptosis 16: 976-989.
10. Udenigwe CC, Ramprasath VR, Aluko R.E., Jones P.J. (2008) Potential of resveratrol in anticancer and anti-inflammatory therapy. Nutr Rev 66: 445-454.
11. Lippi G, Franchini M, Favaloro E.J., Targher G. (2010) Moderate red wine consumption and cardiovascular disease risk: beyond the "French paradox". Semin Thromb Hemost 36: 59-70.
12. Zhong LM, Zong Y, Sun L., Guo JZ, Zhang W, et al. (2012) Resveratrol inhibits inflammatory responses via the mammalian target of rapamycin signaling pathway in cultured LPS-stimulated microglial cells. PloS one 7: e32195.
13. Zong Y, Sun L, Liu B., Deng YS, Zhan D, et al. (2012) Resveratrol inhibits LPS-induced MAPKs activation via activation of the phosphatidylinositol 3-kinase pathway in murine RAW 264.7 macrophage cells. PloS one 7: e44107.
14. Larrosa M, Yanez-Gascon MJ, Selma M.V., Gonzalez-Sarrias A, Toti S, et al. (2009) Effect of a low dose of dietary resveratrol on colon microbiota, inflammation and tissue damage in a DSS-induced colitis rat model. J Agric Food Chem 57: 2211-2220.
15. Bereswill S, Munoz M, Fischer A., Plickert R, Haag LM, et al. (2010) Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation. PloS one 5: e15099.
16. Walle T (2011) Bioavailability of resveratrol. Ann N Y Acad Sci 1215: 9-15.
17. Cottart CH, Nivet-Antoine V, Laguillier-Morizot C, Beaudeux J.L. (2010) Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res 54: 7-16.
18. Hassan-Khabbar S, Cottart CH, Wendum D, Vibert F., Clot JP, et al. (2008) Postischemic treatment by trans-resveratrol in rat liver ischemia-reperfusion: a possible strategy in liver surgery. Liver Transpl 14: 451-459.
19. Larrosa M, Tome-Carneiro J, Yanez-Gascon MJ, Alcantara D, Selma M.V., et al. (2010) Preventive oral treatment with resveratrol pro-prodrugs drastically reduce colon inflammation in rodents. J Med Chem 53: 7365-7376.
20. Rahal K, Schmiedlin-Ren P, Adler J., Dhanani M, Sultani V, et al. (2012) Resveratrol has antiinflammatory and antifibrotic effects in the peptidoglycan-polysaccharide rat model of Crohn's disease. Inflamm Bowel Dis 18: 613-623.
21. Maloy KJ, Powrie F. (2011) Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 474: 298-306.
22. Xavier RJ, Podolsky D.K. (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448: 427-434.
23. Triantafillidis JK, Merikas E, Georgopoulos F. (2011) Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther 5: 185-210.
24. Feghali CA, Wright T.M. (1997) Cytokines in acute and chronic inflammation. Front Biosci 2: d12-26.
25. Beck PL, Wallace J.L. (1997) Cytokines in inflammatory bowel disease. Mediat Inflamm 6: 95-103.
26. Kolios G, Brown Z, Robson R.L., Robertson DA, Westwick J. (1995) Inducible nitric oxide synthase activity and expression in a human colonic epithelial cell line, HT-29. Br J Pharmacol 116: 2866-2872.
27. Kolios G, Manousou P, Bourikas L., Notas G, Tsagarakis N, et al. (2006) Ciprofloxacin inhibits cytokine-induced nitric oxide production in human colonic epithelium. Eur J Clin Invest 36: 720-729.
28. Paul S, Rimando AM, Lee H.J., Ji Y., Reddy BS, et al. (2009) Anti-inflammatory action of pterostilbene is mediated through the p38 mitogen-activated protein kinase pathway in colon cancer cells. Cancer Prev Res 2: 650-657.
29. Atreya I, Atreya R, Neurath M.F. (2008) NF-kappa B in inflammatory bowel disease. J Intern Med 263: 591-596.
30. Feng YJ, Li Y.Y. (2011) The role of p38 mitogen-activated protein kinase in the pathogenesis of inflammatory bowel disease. J Dig Dis 12: 327-332.
31. Broom OJ, Widjaya B, Troelsen J., Olsen J, Nielsen O.H. (2009) Mitogen activated protein kinases: a role in inflammatory bowel disease? Clin Exp Immunol 158: 272-280.
32. Schreiber S, Rosenstiel P, Hampe J., Nikolaus S, Groessner B, et al. (2002) Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut 51: 379-385.
33. Wright K, Ward SG, Kolios G, Westwick J. (1997) Activation of phosphatidy-linositol 3-kinase by interleukin-13. An inhibitory signal for inducible nitric-oxide synthase expression in epithelial cell line HT-29. J Biol Chem 272: 12626-12633.
34. Halliwell B, Whiteman M. (2004) Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br J Pharmacol 142: 231-255.
35. Kaser A, Zeissig S, Blumberg R.S. (2010) Inflammatory bowel disease. Annu Rev Immunol 28: 573-621.
36. Frontela C, Canali R, Virgili F. (2010) Use of dietary phenols to modulate inflammatory bowel response. Gastroenterol Hepatol 33: 307-312.
37. Kuhnle G, Spencer JP, Chowrimootoo G, Schroeter H., Debnam ES, et al. (2000) Resveratrol is absorbed in the small intestine as resveratrol glucuronide. Biochem Biophys Res Commun 272: 212-217.
38. Martin KR (2010) Polyphenols as dietary supplements: A double-edged sword. Dovepress 2: 1-12.
39. Cianciulli A, Calvello R, Cavallo P., Dragone T, Carofiglio V, et al. (2012) Modulation of NF-kB activation by resveratrol in LPS treated human intestinal cells results in downregulation of PGE2 production and COX-2 expression. Toxicol in Vitro 26: 1122-1128.
40. Shuai K, Liu B. (2003) Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 3: 900-911.
41. Capiralla H, Vingtdeux V, Zhao H., Sankowski R, Al-Abed Y, et al. (2012) Resveratrol mitigates lipopolysaccharide- and Abeta-mediated microglial inflammation by inhibiting the TLR4/NF-kappaB/STAT signaling cascade. J Neurochem 120: 461-472.
42. Nardozzi JD, Lott K, Cingolani G. (2010) Phosphorylation meets nuclear import: a review. Cell Commun Signal 8: 32-48.
43. Williams C, Panaccione R, Ghosh S., Rioux K. (2011) Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease. Therap Adv Gastroenterol 4: 237-248.
44. Roux PP, Blenis J. (2004) ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68: 320-344.
45. Roy PK, Rashid F, Bragg J., Ibdah J.A. (2008) Role of the JNK signal transduction pathway in inflammatory bowel disease. World J Gastroenterol 14: 200-202.
46. Kersting S, Behrendt V, Kersting J., Reinecke K, Hilgert C, et al. (2013) The impact of JNK inhibitor D-JNKI-1 in a murine model of chronic colitis induced by dextran sulfate sodium. J Inflamm Res 6: 71-81.
47. Reinecke K, Eminel S, Dierck F., Roessner W, Kersting S, et al. (2012) The JNK inhibitor XG-102 protects against TNBS-induced colitis. PloS one 7: e30985.
48. Zhang Y, Cho YY, Petersen B.L., Zhu F., Dong Z. (2004) Evidence of STAT1 phosphorylation modulated by MAPKs, MEK1 and MSK1. Carcinogenesis 25: 1165-1175.
49. Varinou L, Ramsauer K, Karaghiosoff M., Kolbe T, Pfeffer K, et al. (2003) Phosphorylation of the Stat1 transactivation domain is required for full-fledged IFN-gamma-dependent innate immunity. Immunity 19: 793-802.
50. Goh KC, Haque SJ, Williams B.R. (1999) p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. EMBO J 18: 5601-5608.
51. Vanhatupa S, Ungureanu D, Paakkunainen M., Silvennoinen O. (2008) MAPK-induced Ser727 phosphorylation promotes SUMOylation of STAT1. Biochem J 409: 179-185.
52. Gronholm J, Vanhatupa S, Ungureanu D., Valiaho J, Laitinen T, et al. (2012) Structure-function analysis indicates that sumoylation modulates DNA-binding activity of STAT1. BMC Biochem 13: 20-31.
53. Droescher M, Begitt A, Marg A., Zacharias M, Vinkemeier U. (2011) Cytokine-induced paracrystals prolong the activity of signal transducers and activators of transcription (STAT) and provide a model for the regulation of protein solubility by small ubiquitin-like modifier (SUMO). J Biol Chem 286: 18731-18746.
54. Surh YJ, Kundu JK, Na H.K., Lee J.S. (2005) Redox-sensitive transcription factors as prime targets for chemoprevention with anti-inflammatory and antioxidative phytochemicals. J Nutr 135: 2993S-3001S.